The statistical determination of sample size is mandatory when planning animal experiments, but it is usually difficult to implement appropriately. The main reason is that prior information is hardly ever available, so the assumptions made cannot be verified reliably. This is especially true for pilot experiments. Statistical simulation might help in these situations. We used a Markov Chain Monte Carlo (MCMC) approach to verify the pragmatic assumptions made on different distribution parameters used for power and sample size calculations in animal experiments. Binomial and normal distributions, which are the most frequent distributions in practice, were simulated for categorical and continuous endpoints, respectively. The simulations showed that the common practice of using five or six animals per group for continuous endpoints is reasonable. Even in the case of small effect sizes, the statistical power would be sufficiently large (≥ 80%). For categorical outcomes, group sizes should never be under eight animals, otherwise a sufficient statistical power cannot be guaranteed. This applies even in the case of large effects. The MCMC approach demonstrated to be a useful method for calculating sample size in animal studies that lack prior data. Of course, the simulation results particularly depend on the assumptions made with regard to the distributional properties and effects to be detected, but the same also holds in situations where prior data are available. MCMC is therefore a promising approach toward the more informed planning of pilot research experiments involving the use of animals.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/026119291704500201 | DOI Listing |
ACS Sens
January 2025
Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Solid-phase immunosorbent reactions, such as ELISA, are widely used for detecting, identifying, and quantifying protein markers. However, traditional centimeter scale well-based immunoreactors suffer from low surface-to-volume (S/V) ratios, leading to large sample consumption and a long assay time. Microfluidic technologies, particularly tubular microfluidic immunoreactors, have emerged as promising alternatives due to their high S/V ratios.
View Article and Find Full Text PDFPlant Dis
January 2025
Guizhou University, Jiaxiu South Street, Huaxi District, Guiyang, China, 550025;
Passion fruit (Passiflora edulis) is a commercially important crop known for its nutritional value, high antioxidant content, and use in beverages and desserts. Gulupa baciliform virus A (GBVA), tentatively named Badnavirus in the family Caulimoviridae, is a cryptic circular double-stranded DNA (dsDNA, ≈6,951 bps) virus recently reported in Colombia with asymptomatic infection of passion fruit (Sepúlveda et al. 2022).
View Article and Find Full Text PDFPLOS Digit Health
January 2025
Institute of Mathematical Statistics and Actuarial Science, University of Bern, Bern, Switzerland.
Risk calculators based on statistical and/or mechanistic models have flourished and are increasingly available for a variety of diseases. However, in the day-to-day practice, their usage may be hampered by missing input variables. Certain measurements needed to calculate disease risk may be difficult to acquire, e.
View Article and Find Full Text PDFPsychol Bull
January 2025
Department of Kinesiology, University of North Carolina at Greensboro.
This meta-review provides the first meta-analytic evidence from published meta-analyses examining the effectiveness of acute exercise interventions on cognitive function. A multilevel meta-analysis with a random-effects model and tests of moderators were performed in R. Thirty systematic reviews with meta-analyses (383 unique studies with 18,347 participants) were identified.
View Article and Find Full Text PDFJ Nephrol
January 2025
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.
Background: In an Italian cohort of lupus podocytopathy patients, we aimed to characterize the presenting features, therapy, and outcomes, and explore differences between relapsing and non-relapsing patients.
Methods: We identified 29 patients with lupus podocytopathy from 1994 to 2023 in 11 Italian Nephrology/Rheumatology Units, and divided them into two groups: relapsing and non-relapsing. Given the limited sample size, a p-value ≤ 0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!